Clinical trials: Pyoderma Gangrenosum
Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
- Trial name
- NCT03971643
- Testing
- vilobelimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
- Trial name
- NCT03072953
- Testing
- APD334
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Arena Pharmaceuticals